| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
350,000,000 |
| Market
Cap: |
4.55(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$10.9 - $20.93 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 9.2 |
| Insider 6 Months : 9.2 |
| Insider 3/6 Months : 18.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bausch + Lomb is an eye health company. Co. operates in three segments: Vision Care/Consumer Health Care, which includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins; Ophthalmic Pharmaceuticals, which consists of a line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, dry eyes and retinal diseases; and Surgical, which consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts and vitreous and retinal eye conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
23,695 |
23,695 |
55,945 |
55,945 |
| Total Buy Value |
$267,997 |
$267,997 |
$773,064 |
$773,064 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bonnefoy Luc |
President, Surgical |
• • – |
2025-06-13 |
4 |
D |
$12.33 |
$11,935 |
D/D |
(968) |
73,383 |
|
- |
|
| Paulson John |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
69,965 |
|
- |
|
| Ross Thomas W. Sr. |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
60,391 |
|
- |
|
| Kavanagh Sarah B |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
53,699 |
|
- |
|
| Icahn Brett |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
61,147 |
|
- |
|
| Bernier Nathalie D. |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
69,663 |
|
- |
|
| Robertson Russel C |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
64,914 |
|
- |
|
| Hu Gaoxiang |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
61,147 |
|
- |
|
| Ling Karen |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
37,676 |
|
- |
|
| Von Eschenbach Andrew C. |
Director |
• • – |
2025-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,338 |
62,086 |
|
- |
|
| Saunders Brent L |
CEO and Chairman of the Board |
• • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
741,156 |
|
- |
|
| Saunders Brent L |
CEO and Chairman of the Board |
• • – |
2025-05-22 |
4 |
B |
$11.28 |
$248,072 |
D/D |
22,000 |
719,156 |
2.81 |
10% |
|
| Von Eschenbach Andrew C. |
Director |
• • – |
2025-05-02 |
4 |
B |
$11.76 |
$19,925 |
D/D |
1,695 |
41,748 |
2.39 |
8% |
|
| Robertson Russel C |
Director |
• • – |
2025-05-01 |
4 |
A |
$11.59 |
$25,614 |
D/D |
2,210 |
44,576 |
|
- |
|
| Paulson John |
Director |
• • – |
2025-05-01 |
4 |
A |
$11.59 |
$21,870 |
D/D |
1,887 |
49,627 |
|
- |
|
| Stewart Andrew J. |
See remarks |
• • – |
2025-04-24 |
4 |
D |
$13.89 |
$54,921 |
D/D |
(3,954) |
62,930 |
|
- |
|
| Bailey A Robert D |
EVP & Chief Legal Officer |
• • – |
2025-04-24 |
4 |
D |
$13.89 |
$135,858 |
D/D |
(9,781) |
170,576 |
|
- |
|
| Bonnefoy Luc |
President,Surgical |
• • – |
2025-02-28 |
4 |
D |
$16.00 |
$66,224 |
D/D |
(4,139) |
74,351 |
|
- |
|
| Munsch Frederick |
SVP, Controller and CAO |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
18,581 |
71,294 |
|
- |
|
| Eldessouky Sam |
EVP and CFO |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
59,459 |
282,295 |
|
- |
|
| Saunders Brent L |
CEO and Chairman of the Board |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
168,168 |
697,156 |
|
- |
|
| Hashad Yehia |
EVP of R&D and CMO |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
25,225 |
119,580 |
|
- |
|
| Bailey A Robert D |
EVP & Chief Legal Officer |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
40,540 |
180,357 |
|
- |
|
| Stewart Andrew J. |
See remarks |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,423 |
66,884 |
|
- |
|
| Bonnefoy Luc |
President,Surgical |
• • – |
2025-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,423 |
78,490 |
|
- |
|
132 Records found
|
|
Page 1 of 6 |
|
|
0.61 (4.92%) 
